Marijn Dekkers, Novalis LifeSciences founder and chairman (Martin Meissner/AP Images)

Dekkers-found­ed in­vest­ment firm No­valis Life­Sciences rais­es $300M for sec­ond fund and adds to the team

Two years ago, life sci­ences VC No­valis Life­Sciences an­nounced that it had raised $85 mil­lion for its first fund, look­ing to in­vest in­to any­where be­tween 8 to 12 com­pa­nies “in var­i­ous seg­ments of the life sci­ence in­dus­try.” No­valis now wants to go big­ger, an­nounc­ing ear­li­er this week it raked in $300 mil­lion for No­valis Life­Sciences In­vest­ments II.

The New Hamp­shire-based VC, found­ed in 2017 by Gink­go Bioworks board chair­man and ex-Bay­er CEO Mar­i­jn Dekkers, plans to in­vest in­to any­where be­tween 10 and 15 more life sci­ence com­pa­nies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.